A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Key facts
- Who runs it
- BeOne Medicines
- Where
- Baltimore, Boston, Charlotte, Columbus, Dallas, Denver, Duarte, Hattiesburg, Miami, New York, Richmond, Rochester, Salt Lake City, Seattle, Warrenville, Washington D.C., and Waukee, United StatesSee the 17 sitesAlso in 8 other countries, 50 sites
- Trial code
- NCT05952037
- EU 2023-503235-18-00
- U1111-1291-4524
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 114 people enrolled
- Started
- 23 Oct 2023
- Expected to end
- Aug 2028
- Type of study
- Interventional, 4 groups
- Treatments tested
- Sonrotoclax
- Zanubrutinib
- Record updated
- 20 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Clinical and definitive histologic diagnosis of WM
- Meeting ≥ 1 criterion for treatment according to consensus panel criteria from the 2nd International Workshop on Waldenström's Macroglobulinemia (IWWM)
- For Cohorts 1-3, refractory or relapsed disease at study entry unless participants had intolerance to the most recent therapy. Refractory disease is defined as not attaining at least a major response, or progressing while on or within 6 months of completing therapy. Relapsed disease is defined as attaining at least a major response to therapy and meeting the criteria for disease progression beyond 6 months after completing therapy
- For Cohort 4, patients must not have received prior therapy for WM (except for plasmapheresis)
- Adequate organ function
Who cannot take part
- Uncontrolled active systemic infection or recent infection requiring parenteral antimicrobial therapy that was completed ≤ 14 days before the first dose of the study drug; Note: Other protocol defined Inclusion/Exclusion criteria may apply
- History of other malignancies ≤ 2 years before study entry
- Central nervous system (CNS) involvement by WM
- Transformation to aggressive lymphoma, such as diffuse large B-cell lymphoma
Where in United States
Also in 8 other countries, 50 sites
- University of Maryland Greenebaum Comprehensive Cancer CenterBaltimore, United States
- Dana-Farber Cancer InstituteBoston, United States
- Atrium Health Levine Cancer Institute (Lci)Charlotte, United States
- Ohio State University Comprehensive Cancer CenterColumbus, United States
- UT Southwestern Medical CenterDallas, United States
- Colorado Blood Cancer InstituteDenver, United States
- City of Hope National Medical CenterDuarte, United States
- Hattiesburg Hematology and Oncology ClinicHattiesburg, United States
- University of MiamiMiami, United States
- Memorial Sloan Kettering Cancer Center MskccNew York, United States
- Virginia Commonwealth University/Massey Cancer CenterRichmond, United States
- Mayo Clinic - RochesterRochester, United States
- Huntsman Cancer InstituteSalt Lake City, United States
- University of WashingtonSeattle, United States
- Northwestern Medicine Cancer CenterWarrenville, United States
- MedStar Georgetown University HospitalWashington D.C., United States
- Mission Cancer and BloodWaukee, United States
About the trial
What the trial wants to find out
This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.
The 4 groups in the trial
- Cohort 1Treatment being tested
Participants with R/R disease to both Bruton tyrosine kinase (BTK) inhibitor and anti-CD20 antibody-based systemic therapy containing chemotherapy or proteasome inhibitor will receive sonrotoclax at a standard dose, given orally once daily.
Treatment: Sonrotoclax
- Cohort 2Treatment being tested
Participants with R/R disease to anti-CD20 antibody-based systemic therapy containing chemotherapy or proteasome inhibitor and were intolerant to BTK inhibitor will receive sonrotoclax at a standard dose, given orally once daily.
Treatment: Sonrotoclax
- Cohort 3Treatment being tested
Participants with R/R disease to a BTK inhibitor treatment and are unsuitable for chemoimmunotherapy will receive sonrotoclax at a standard dose, given orally once daily.
Treatment: Sonrotoclax
- Cohort 4Treatment being tested
Participants with previously untreated WM will receive sonrotoclax and zanubrutinib combination therapy for a fixed duration.
Treatment: Sonrotoclax and Zanubrutinib
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
- Record updated
- 20 October 2026